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Abstract
Background: Vinblastine (VBL) is the standard treatment for systemic Langerhans cell histiocytosis (LCH), but little
is known about its efficacy in central nervous system (CNS) mass lesions.
Methods: A retrospective chart review was conducted. Twenty patients from the French LCH Study Group register
met the inclusion criteria. In brief, they had CNS mass lesions, had been treated with VBL, and were evaluable for
radiologic response.
Results: The median age at diagnosis of LCH was 11.5 years (range: 1-50). Intravenous VBL 6 mg/m
2 was given in
a 6-week induction treatment, followed by a maintenance treatment. The median total duration was 12 months
(range: 3-30). Eleven patients received steroids concomitantly. Fifteen patients achieved an objective response; five
had a complete response (CR: 25%), ten had a partial response (PR: 50%), four had stable disease (SD: 20%) and
one patient progressed (PD: 5%). Of interest, four out of the six patients who received VBL without concomitant
steroids achieved an objective response. With a median follow-up of 6.8 years, the 5-year event-free and overall
survival was 61% and 84%, respectively. VBL was well-tolerated and there were no patient withdrawals due to
adverse events.
Conclusion: VBL, with or without steroids, could potentially be a useful therapeutic option in LCH with CNS mass
lesions, especially for those with inoperable lesions or multiple lesions. Prospective clinical trials are warranted for
the evaluation of VBL in this indication.
Background
Langerhans cell histiocytosis (LCH) is a rare disease char-
acterized by an accumulation of Langerhans cells [1].
Clinical presentation ranges from isolated benign locali-
zation to multisystemic aggressive lesions. Although it is
most common in children under 15 years of age, it may
occur at any age [2-4]. Central nervous system (CNS)
complications of LCH occur in 1-11% of patients [4-6]
and can be subdivided clinically into two subtypes, each
corresponding with a distinct pathophysiology. The first
type is the ‘neurodegenerative-like’ form, characterized
by neuronal cell loss and a progressive cerebellar ataxia,
frequently combined with pyramidal syndrome and cog-
nitive dysfunction [7-12]. The second type is the tumoral
or mass lesions-type presenting as unique or multiple
contrast-enhancing space-occupying lesions [13-16]. In
this latter form, the lesions can be located anywhere in
the CNS but are most commonly found in the hypotha-
lamo-pituitary region. Optimal treatment for LCH with
CNS mass lesions is not yet well defined, and depends on
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any medium, provided the original work is properly cited.the site of the disease [5]. Vinblastine (VBL) chemother-
apy is the standard treatment for aggressive systemic
LCH [17], but little is known about its efficacy in LCH
with CNS mass lesions. In order to evaluate the efficacy
and safety of VBL, we retrospectively studied patients
from the French LCH register who had received VBL for
LCH with CNS mass lesions.
Methods
Patients with CNS mass lesions were identified from the
French LCH Study Group register. This database was
initially created for a retrospective study of patients with
LCH between 1983 and 1993, but from 1994 enrolment
into the database was conducted prospectively. Since
2008 this collection of data has been recognized as a
national register by the French health authorities and has
been verified against multiple separate sources [18]. The
database has been declared to the French computer
watchdog authorities (Comité Consultatif pour le Traite-
ment de l’Information en matière de Recherche pour la
Santé [CCTIRS] and Commission Nationale Informa-
tique et Liberté [CNIL]), and the patient must provide
informed consent to be included in the register. Data
monitoring, based on medical charts, was conducted by a
clinical research associate who visited each center.
Patients listed in the register were included in the study
if they had: i) LCH with CNS mass lesions defined as the
presence of a contrast-enhancing space-occupying CNS
lesion occurring in a patient with either proven systemic
LCH or who meets the pathologic criteria for LCH on
CNS biopsy according to the histiocyte society (CD1a
positive cells or Birbeck granules)[19]; ii) received treat-
ment with VBL either as initial or salvage treatment; and
iii) had measurable disease with lesions visible after con-
trast-enhanced magnetic resonance imaging (MRI) and
were evaluable for tumor response (i.e. availability of pre
and post-therapeutic MRIs for review). Imaging studies
performed before and after treatment with VBL were
reviewed independently by three investigators (NMD,
SNWT and CG).
The primary endpoint was the radiologic response to
VBL therapy. Response was assessed by determining the
product of the two largest perpendicular diameters of the
lesion on the axial T1 planes of the MRI scan, as pre-
viously reported by Macdonald [20]. A complete
response (CR) was defined as complete disappearance of
all mass lesions; a partial response (PR) was defined as a
greater than 50% reduction in the size of all measurable
mass lesions, and patients must be on stable or reduced
doses of corticosteroids and show a stable or improved
neurologic status. Progressive disease (PD) was defined
as a greater than 25% increase in the size of measurable
mass lesion(s) or as tumor-related neurologic deteriora-
tion. Stable disease (SD) was defined as any other clinical
status not meeting the criteria for CR, PR, and PD. Sec-
ondary endpoints included event-free survival, number of
relapses, endocrine sequelae, death and overall survival.
Event-free survival was defined as the time from start of
VBL treatment until the event (death, relapse or progres-
sion), or the date of last examination if no event
occurred. Initial failure (PD) was considered as an event
and, in this instance, the time-to-event was equal to zero.
Relapse was defined as disease progression after an initial
favorable response. The Kaplan-Meier method was used
to estimate overall survival and event-free survival. The
cut-off date for data analysis was November 15, 2010.
Results
Patients
Among 1411 patients from the French LCH Study
Group register, 57 were identified with CNS Langerhans
cell histiocytic mass lesions. Of these, 37 were excluded:
two had been treated only with surgery, four had
received 2-chlorodeoxyadenosine (2-cda) as initial ther-
apy, four were under observation, ("watchful waiting”),
two had received other chemotherapy and radiotherapy
treatments, and the remaining 26 did not have MRI
scans accessible for review. The retained 20 patients ful-
filled the inclusion criteria of the study, including having
received VBL treatment and were evaluable for an
objective response. CNS lesions were documented by
MRI imaging in all patients, and additionally in 9
patients by CNS mass lesion biopsy to confirm tumor
immunohistochemistry.
Patient characteristics
The main clinical characteristics of the patients are
summarized in Table 1. Of the 20 patients, 12 were
female and 8 male. The median age of LCH diagnosis
onset was 11.5 years (range: 1-50) and the median age
of neurologic involvement diagnosis was 12 years
(range: 3-53). Neurologic diagnosis were simultaneous
with the first occurrence of LCH in 12 patients and
occurred during a reactivation in 8 patients (after a
median delay of 3.7 years since the first occurrence of
LCH).
The CNS mass lesions were solitary (n = 15) or multifo-
cal (n = 5). Lesions were located solely in the hypotha-
lamo-pituitary region in 14 patients and were solely
extrahypothalamic in 4 patients; 2 patients had both
hypothalamic and extrahypothalamic lesions. All three
patients with brainstem mass lesions were adults. In addi-
tion to a mass lesion, three patients had typical bilateral
non-enhancing lesions of the cerebellum white matter,
which are usually observed in the neurodegenerative form
of LCH (patients #2, #5 and #6). Symptoms of CNS dis-
ease were linked to the site of the CNS lesions (diabetes
insipidus, cognitive impairment, seizures, hemiparesis,
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Page 2 of 9cerebellar ataxia, cranial nerve palsies). CNS disease was
associated with multisystemic LCH in 13 patients (bone,
skin and lung involvement) and isolated in 7 patients.
Eighteen patients were previously untreated before VBL
therapy, and two patients were previously treated (patient
#10 with steroids and patient #5 with combination che-
motherapy of methotrexate plus etoposide). Intravenous
VBL was delivered at a standard dose (6 mg/m
2), given
once weekly for 6 weeks (induction treatment) followed by
a maintenance dose every 3 weeks. All patients received
the 6-week induction treatment; the median duration of
maintenance treatment was 12 months (range 3-30). Ele-
ven patients were already receiving steroids prior to initia-
tion of VBL or received steroids concomitantly to VBL as
part of the chemotherapy regimen (Table 2).
Primary endpoint: response to treatment
Fifteen patients achieved an objective response, includ-
ing five complete responses (CR 25%) and 10 partial
responses (PR 50%); four patients had stable disease (SD
20%) and one had progressive disease (PD 5%). Of
interest, four out of the six patients who received VBL
but not steroids achieved an objective response (1 CR, 3
P R ,1S D ,1P D ;F i g u r e s1 ,2a n d3 ) .A f t e re v a l u a t i o no f
the initial response, the 10 patients with a partial
response continued VBL maintenance therapy until the
end of the therapy or in one case, until disease progres-
sion (Table 2).
Secondary endpoints
Treatment with VBL was well-tolerated. The most severe
adverse events were mild peripheral neuropathy (grade 2;
n = 2, patients #10 and #12) and increased liver enzymes
(grade 2; n = 2, patients #14 and #16). There were no
reports of patients withdrawing from treatment as a
result of adverse events.
After a median follow-up of 6.8 years (from VBL-treat-
ment onset), the 2- and 5-year event-free survivals were
67% and 61%, respectively, with a plateau after 3 years
(Figure 4). At the time of analysis, seven patients had
relapsed. Details of therapy for relapse are included in
Table 2: three patients were retreated with VBL
Table 1 Patient demographic and clinical characteristics
Patient Sex Age at diagnosis
of LCH (years)
Age at diagnosis of CNS
involvement (years)
Localisation of CNS
mass lesion
Other sites of
LCH involvement
Symptoms
1 F 10 12 hp Bone, skin Diabetes insipidus
2 F 50 53 p (brainstem) mastoid Cerebellar ataxia
3 F 26 28 hp None Cognitive impairment, bulimia,
diabetes insipidus
4 M 9 9 hp None Diabetes insipidus
5 M 21 34 p (multifocal: frontal and
brainstem)
Bone, lung Cerebellar ataxia, cranial nerve palsies,
hemiparesis, diabetes insipidus
6 F 2 3 hp Skin Diabetes insipidus
7 M 41 44 hp Lung Cognitive impairment, diabetes
insipidus
8 F 3 3 hp Skin, bone, thyroid Diabetes insipidus
9 F 7 7 hp Skin, lung Diabetes insipidus
10 F 1 10 hp Skin, bone, Visual field defect
11 F 4 4 hp and m Bone Diabetes insipidus
12 M 26 30 hp and p (brainstem) Skin, lung, parotid,
liver
Hemiparesis, headaches
13 M 35 35 hp Bone Diabetes insipidus
14 F 15 16 hp None Headaches
15 F 2 12 p (multifocal: temporal,
frontal, parietal lobes)
Bone, skin Diabetes insipidus
16 M 28 28 hp Bone Cognitive impairment, diabetes
insipidus
17 F 15 15 hp None Visual field defect, diabetes insipidus
18 M 1 5, 5 hp Bone, skin Diabetes insipidus
19 F 12 12, 1 hp None Diabetes insipidus
20 M 11 11 p (cerebellum) None Cerebellar ataxia
CNS = central nervous system, F = female, hp = hypothalamo-pituitary region involvement, LCH = Langerhans cell histiocytosis, M = male, p = parenchymal
involvement, m = meningeal involvement.
Ng Wing Tin et al. Orphanet Journal of Rare Diseases 2011, 6:83
http://www.ojrd.com/content/6/1/83
Page 3 of 9Table 2 Response to treatment and outcome
Patient Treatment
duration
(months)
a
Concomitant
steroids (Y/
N)
Radiologic
response
Change to
therapeutic
regimen after
radiologic
evaluation (Y/N)
[details]
Relapse (Y/N)
[details]
Treatment for
relapse [details]
Endocrine
sequelae
NDS/cognitive
impairment
(time since CNS
mass lesions)
Final MRI features Vital status at
follow-up visit
[duration of
follow-up
(years)]
d
1 21 Y CR N N DI, GHD None Normal L [9.0]
2 3 N PD Y [therapy
withdrawn]
N DI NDS
(simultaneously)
Neurodegenerative
lesions
D [4.4]
3 17 N CR N N Panhypopituitarism NDS (about 1 y
after mass lesion)
Atrophy L [6.8]
4 12 N PR N N DI, GHD, obesity,
hypothalamic
syndrome
Behavioral
disturbance -
several months
after the end of
therapy
Residual lesions
c L [6.7]
5 13 Y SD N Y [brain stem,
month 12]
IC plus autograft
[resulting in PR,
subsequent death
from sepsis]
DI NDS
(simultaneously)
Tumoral lesion and
neurodegenerative
lesion
D [7.1]
6 13 N PR N N DI NDS (3 years after
mass lesion)
No tumoral lesion.
Neurodegenerative
lesions
L [7.2]
7 18 Y SD N Y [temporal
lobe, month
16]
VBL [death 1 month
after VBL]
DI NDS
(simultaneously)
Tumoral lesion and
neurodegenerative
lesion
D [4.4]
83 0 Y P R N Y
[hypothalamus,
month 15]
VBL DI None Residual lesions
c L [10.9]
9 12 N SD N N DI None Residual lesions
c L [3.8]
10 18 Y CR N N DI, morbid obesity,
hypothalamic
syndrome
None Residual lesions
c L [7.4]
11 7 Y PR N Y
[hypothalamus,
month 19]
VBL [PR) DI None Residual lesions
c L [1.4]
12 6 Y SD N Y [brain stem,
month 47]
2-cda [relapse at 5
months] Subsequent
treatment with
autograft [CR/
remission]
DI None Residual lesions
c L [8.3]
13 10 Y PR N DI None Normal L [10.0]
14 12 N PR N Y
[hypothalamus
month 3]
VBL, [VBL allergy
b]
Then RT [failure], then
2-cda [CR]
Panhypopituitarism None Residual lesions
c L [10.9]
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9Table 2 Response to treatment and outcome (Continued)
15 12 Y PR N DI, GHD None Normal L [21.3]
16 5 Y CR N Y [brainstem,
month 20]
2-cda [frank
progression leading
to death]
DI Cognitive
impairment -
progressive after
end of initial
therapy
Disease progression
(to brain stem)
D [1.9]
17 12 Y PR N Y [bone only) VBL plus steroid DI None Residual lesions
c L [7.3]
18 4 (ongoing) Y PR N N DI None Residual lesions
c L [0.4]
19 12 Y PR N N Panhypopituitarism None Residual lesions
c L [5.0]
20 11 Y CR N N None None Normal L [6.9]
2-cda = 2-chlorodeoxyadenosine, CR = complete response, D = deceased; DI = central diabetes insipidus, IC = intensive chemotherapy, GHD = growth hormone deficiency, L = living; MRI = magnetic resonance
imaging; N = no, NDS = neurodegenerative syndrome; PD = progressive disease, PR = partial response, RT = radiotherapy, SD = stable disease, VBL = vinblastine, Y = yes.
a The duration of treatment is calculated from the start of VBL to the end of the maintenance treatment, i.e. the last pulse of VBL and/or the last steroid dose.
b Repeated skin risk after VBL pulses, increasing after repeated injections.
c Residual lesion are considered if the mass lesion remained unchanged during sequential MRI at least during a 6-month interval.
d Duration is calculated from the time of diagnosis of CNS mass lesions.
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9chemotherapy and responded, one patient underwent
radiotherapy but with no improvement, but did respond
thereafter to treatment with 2-cda. Two patients
responded to an intensive chemotherapy regimen with
hematopoietic stem cell support (the latter after failure of
2-cda treatment) but one among the two died from com-
plications of neurodegenerative CNS LCH. Finally one
patient did not respond to 2-cda treatment and experi-
enced rapid tumoral progression leading to death.
The 5-year overall survival rate was 84% (95% CI: 58-
94%). Four patients died, at 1, 14, 21 and 24 months after
the initiation of VBL treatment. Of note, three of these
patients (2# 5# 16#) had a mass lesion in the brainstem
and two (patient 2# and 5#) had bilateral non-enhancing
lesions of the cerebellum white matter. The immediate
cause of death was a pulmonary embolism (n = 1)
(patient 7#), sepsis (n = 1) (patient 5#) and neurologic
disease progression (n = 2) (patient 5# and 16#). Endo-
crine sequelae were observed in 19 patients: with central
diabetes insipidus (CDI) in 19 patients, growth hormone
deficiency in 6 patients and panhypopituitarism in 3
patients. CDI was always present at the diagnosis of CNS
Figure 1 Complete response to vinblastine chemotherapy. Dura mater lesion. Axial T1-weighted magnetic resonance imaging (MRI) with
gadolinium before treatment with vinblastine (A) and 8 months after treatment initiation showing a complete response (B).
Figure 2 Partial response to vinblastine chemotherapy. Hypothalamic and temporal lesions. Coronal T1-weighted magnetic resonance
imaging (MRI) with gadolinium before treatment with vinblastine (A) and 12 months after treatment initiation, showing a partial response (B).
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Page 6 of 9mass lesions and persisted, even in the case of CR. The
age of patients at diagnosis, specifically those over 18
years old, was associated with a poorer outcome com-
pared with those younger than 18 years old, both in
terms of event-free survival (5-year event-free survival
rates of 28% vs 90%; p = 0.005) and overall survival (5-
year overall survival rate of 57% vs 100%; p = 0.0052).
Discussion
Among 20 patients with LCH and CNS mass lesions, a
75% objective response rate was observed following VBL
chemotherapy. Because the majority of patients received
steroids at the same time (as an anti-inflammatory or as
part of their chemotherapy regimen), it is difficult to
attribute the treatment response solely to VBL. However,
in the subgroup if patients who did not receive any ster-
oids in their initial treatment, the objective response rate
was comparable with the overall response rate of the
steroid-treated group (2/3 of the patients i.e. 4 respon-
d e r so u to f6p a t i e n t s ) .T h i ss u g g e s t st h a tV B L ,e i t h e ra s
monotherapy or in combination with steroids, is highly
active in LCH with CNS mass lesions. Additionally,
Figure 3 Complete response to vinblastine chemotherapy. Third ventricle lesion. Axial T1-weighted magnetic resonance imaging (MRI) with
gadolinium before vinblastine treatment (A) and 6 months after treatment initiation, showing a complete response (B).
Figure 4 Event-free survival calculated by the Kaplan-Meier method. Events are progressive disease or any new progression after initial
control of the CNS lesion. Duration is expressed in years.
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Page 7 of 9patients who respond do not appear to become desensi-
tized to VBL over time: three patients who relapsed after
VBL treatment were successfully retreated at recurrence
with the same VBL regimen. Our results confirm and
extend those of case reports; an objective response to
VBL as primary or salvage therapy was observed in four
out of five patients in LCH with CNS mass lesions
[21-25]. Contrary to its effect on mass lesions, VBL
seems to have no effect on neurodegenerative lesions and
their related symptoms, which seem to arise via patho-
physiologic mechanisms distinct from CNS mass lesions
[7]. Interestingly, the patients in this study that demon-
strated a mixed form of LCH worsened.
VBL, a vinca alkaloid, is a key drug in the treatment of
multisystem LCH, where response rates of up to 70% have
been achieved [17,26], which is comparable with the
response rate observed in our present study for CNS mass
lesions. This suggests that VBL penetrates the blood-brain
barrier sufficiently so as to have a therapeutic effect on
CNS mass lesions. In addition, VBL is well tolerated and
can be delivered for a prolonged time without significant
cumulative toxicity, as observed in the present study and
elsewhere [26].
The purine substrate analogue 2-cda has been also been
shown to be similarly effective for systemic LCH [27], but
it is widely considered more appropriate as a second-line
therapy [28]. Paradoxically, its use has been more fre-
quently reported than the use of VBL in patients with
CNS mass lesions: Dhall et al reported a series of 12
patients treated with 2-cda who achieved an objective
response (8 CR and 4 PR) [29]. Similarly to the patients in
this study, those in the Dhall group had CNS lesions pri-
marily in the hypothalamo-pituitary region (n = 10), while
the remaining two patients had extra-hypothalamic lesions
located in the dura mater. While 2-cda treatment yielded a
high response rate, it was also associated with substantial
toxicity, especially prolonged bone marrow suppression
previously described in other studies [30]. In light of this,
2-cda would be likely to be best utilized as second-line
chemotherapy after VBL in relapsed or treatment-refrac-
tory patients. Anecdotal cases of LCH with CNS mass
lesions treated with intensive chemotherapy plus hemato-
poietic stem cell support have been reported, with a pro-
longed response observed in some patients, but absence of
response in others [31].
Conclusion
Our results suggest that VBL is a therapeutic option for
CNS mass lesions in LCH, and support the continued
evaluation of VBL in prospective trials. Chemotherapy
with VBL appears to be of particular interest for the
treatment of lesions in non-operable locations, multifo-
cal lesions or secondary CNS lesions in the setting of
systemic active LCH disease.
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